Flu Season is Approaching: Upgraded Flu A/B Antibodies with No Cross-Reactivity | Cnpair

Cnpair FluA B Performance Validation No Cross Reactivity

Influenza A and B remain common causes of seasonal respiratory infections. We are pleased to share the performance of Cnpair’s Flu A/B Antibodies raw materials, designed to support the development of high-quality immunoassays, especially lateral flow (LF) assays. Key performance highlights include:
1️⃣No cross-reactivity between Flu A/B
2️⃣Excellent specificity against 20 common interferents
3️⃣High detection sensitivity

Internal Validation Data

* Sample Source:2nd National Reference Panel for Influenza A/B Viral Antigens Detection Kit

· No Cross-Reactivity

Cnpair’s Flu A/B combination test card was evaluated using the 2nd National Reference Panel for Influenza A/B Viral Antigens Detection Kit.

ContentPathogenDetection lineCnpair test result
Positive referenceB/YamagataA–
B4
B/YamagataA–
B2.5
B/VictoriaA–
B5
B/VictoriaA–
B6
2009 H1N1A7
B–
2009 H1N1A2.5
B–
Seasonality H1N1A2.5
B–
Influenza A H3N2A6
B–
Influenza A H3N2A5
B–
Influenza A H7N9A5
B–

Each Influenza A subtype (2009 H1N1, Seasonality H1N1, H3N2, H7N9) produced a signal only on the A line, while each Influenza B subtype (B/Victoria, B/Yamagata) produced a signal only on the B line.

Colloidal gold colorimetric test score card

· Specificity Performance

Cnpair’s Flu A/B combination test cards were evaluated against 20 common pathogens and medications.

ContentPathogenDetection lineCnpair test result
Negative referenceStaphylococcus aureusA–
B–
Streptococcus pneumoniaeA–
B–
Measles virusA–
B–
Mumps virusA–
B–
Adenovirus type 3A–
B–
Adenovirus type 7A–
B–
Mycoplasma pneumoniaeA–
B–
Parainfluenza type 2A–
B–
MetapneumovirusA–
B–
Coronavirus OC43A–
B–
Coronavirus 229EA–
B–
Bacillus pertussisA–
B–
Epstein-barr virusA–
B–
Enterovirus CA16A–
B–
Respiratory syncytial virusA–
B–
Rhinovirus group AA–
B–
Neisseria meningitidisA–
B–
COVID-19 OmicronA–
B–
Negative swabA–
B–
Dexamethasone sodium phosphate, 0.4mg/mLA–
B–

All 20 pathogens and medications, including Staphylococcus aureus, Streptococcus pneumoniae, RSV, and COVID-19 Omicron, showed no visible signal on either the A or B line.

· LoD Performance

Cnpair’s Flu A/B combination test cards were validated with the National Reference Panel on lateral flow.

ContentIDPathogenSpecified detection concentration(U/mL)
Limit of DetectionL12009 H1N11.3×10⁵
L2Seasonality H1N12.7×10⁵
L3B/Victoria1.7×10⁵
L4B/Yamagata1.9×10⁵
L5H3N22.3×10⁵
L6H7N92.9×10⁵

Detection was achieved across all six subtypes, with LoD values ranging from 1.3×10⁵ U/mL for 2009 H1N1 to 2.9×10⁵ U/mL for H7N9.

Whether you are developing a new product or optimizing the performance of an existing one, our Flu A/B antibody portfolio can provide a reliable foundation for your diagnostic development.

1. Which suppliers provide Flu A/B antibodies with no cross-reactivity for lateral flow assays?

Cnpair provides Flu A/B antibody raw materials designed for lateral flow assays, with no detectable cross-reactivity between Influenza A and Influenza B.

2. What is the limit of detection for Cnpair’s Flu A/B antibodies?

Validated with the 2nd National Reference Panel, Cnpair’s Flu A/B combination test cards achieved 100% detection on lateral flow, with LoD values ranging from 1.3×10⁵ to 2.9×10⁵ U/mL across 2009 H1N1, Seasonality H1N1, B/Victoria, B/Yamagata, H3N2, and H7N9.

3. Do Cnpair’s Flu A/B antibodies cross-react with other respiratory pathogens?

No. Cnpair’s Flu A/B combination test cards were evaluated against 20 common pathogens and medications, including Staphylococcus aureus, Streptococcus pneumoniae, RSV, and COVID-19 Omicron, with no visible signals observed.

Online Inquiry